The FDA has selected Johns Hopkins University, Stanford University and the University of California, San Francisco, for a new initiative aimed at streamlining the drug development and approval process.
Boston Scientific is joining forces with Optum as the healthcare data company's first medical device partner.
Regeneron is turning to gene therapy research to look for a successor to its blockbuster wet AMD drug Eylea.
Months removed from a field-affirming deal with Johnson & Johnson, Second Genome has struck up another Big Pharma partnership, teaming up with Pfizer to launch a sizable study in hopes of better understanding the link between obesity and the microbiome.
Vaccine sales can only grow as much as patient adherence to immunization recommendations allows, but Merck is rolling out a new initiative that could give its vaccines unit a boost.
Teleflex has signed a deal with robotic surgery giant Intuitive Surgical to manufacture access ports for the company's latest da Vinci device.
France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But the CEO says he's laying the groundwork for a late-stage study, confident that he can find another partner.
Merck is looking to Lexington, MA-based Agenus to give the pharma giant an edge in the race to develop new immuno-oncology drugs.
Toxicology specialist Harlan Laboratories is looking to tap the growing market for contract research in Oceania, signing a deal with local outfit Invenium Pharmacology to do so.
Rutgers University has landed a $26 million grant from the U.S. National Institute of Allergy and Infectious Diseases to develop new antibiotics to curb the impending crisis of antimicrobial drug resistance.